FLT1
Prijeđi na navigaciju
Prijeđi na pretragu
| edit |
| Tirozinska kinasa 1 srodna sa Fms | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
 PDB prikaz baziran na 1flt. | |||||||||||
| Dostupne strukture | |||||||||||
| 1FLT, 1QSV, 1QSZ, 1QTY, 1RV6, 2XAC, 3HNG | |||||||||||
| Identifikatori | |||||||||||
| Simboli | FLT1; FLT; FLT-1; VEGFR-1; VEGFR1 | ||||||||||
| Vanjski ID | OMIM: 165070 MGI: 95558 HomoloGene: 134179 GeneCards: FLT1 Gene | ||||||||||
| EC broj | 2.7.10.1 | ||||||||||
| |||||||||||
| Pregled RNK izražavanja | |||||||||||
 | |||||||||||
| podaci | |||||||||||
| Ortolozi | |||||||||||
| Vrsta | Čovek | Miš | |||||||||
| Entrez | 2321 | 14254 | |||||||||
| Ensembl | ENSG00000102755 | ENSMUSG00000029648 | |||||||||
| UniProt | P17948 | P35969 | |||||||||
| Ref. Sekv. (iRNK) | NM_001159920 | NM_010228 | |||||||||
| Ref. Sekv. (protein) | NP_001153392 | NP_034358 | |||||||||
| Lokacija (UCSC) | Chr 13: 28.87 - 29.07 Mb | Chr 5: 147.56 - 147.73 Mb | |||||||||
| PubMed pretraga | [1] | [2] | |||||||||
Receptor 1 vaskularnog endotelnog faktora rasta je protein koji je kod ljudi kodiran FLT1 genom.[1]
Onkogen FLT pripada src genskoj familiji i srodan je onkogenu ROS (MIM 165020). Poput drugih članova ove familije, on no je tirozinska proteinska kinaza koja učestvuje u kontroli ćelijske proliferacije i diferencije. Sekvenca FLT gena podseća na FMS gen (MIM 164770) i stoga su Yoshida et al. (1987) predložili ime FLT kao akronim za FMS-sličnu tirozinsku kinazu.[[2]
Interakcije[uredi | uredi kod]
FLT1 formira interakscije sa PLCG1[3] i vaskularnim endotelnim faktorom rasta.[4][5]
Vidi još[uredi | uredi kod]
Reference[uredi | uredi kod]
- ↑ Shibuya M, Yamaguchi S, Yamane A, Ikeda T, Tojo A, Matsushime H, Sato M (May 1990). „Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family”. Oncogene 5 (4): 519–24. PMID 2158038.
- ↑ „Entrez Gene: FLT1 fms-related tyrosine kinase 1 (vascular endothelial growth factor/vascular permeability factor receptor)”.
- ↑ Cunningham, S A; Arrate M P; Brock T A; Waxham M N (Nov 1997). „Interactions of FLT-1 and KDR with phospholipase C gamma: identification of the phosphotyrosine binding sites”. Biochem. Biophys. Res. Commun. (UNITED STATES) 240 (3): 635–9. DOI:10.1006/bbrc.1997.7719. ISSN 0006-291X. PMID 9398617.
- ↑ Olofsson, B; Korpelainen E, Pepper M S, Mandriota S J, Aase K, Kumar V, Gunji Y, Jeltsch M M, Shibuya M, Alitalo K, Eriksson U (Sep 1998). „Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells”. Proc. Natl. Acad. Sci. U.S.A. (UNITED STATES) 95 (20): 11709–14. DOI:10.1073/pnas.95.20.11709. ISSN 0027-8424. PMC 21705. PMID 9751730.
- ↑ Makinen, T; Olofsson B; Karpanen T; Hellman U; Soker S; Klagsbrun M; Eriksson U; Alitalo K (Jul 1999). „Differential binding of vascular endothelial growth factor B splice and proteolytic isoforms to neuropilin-1”. J. Biol. Chem. (UNITED STATES) 274 (30): 21217–22. DOI:10.1074/jbc.274.30.21217. ISSN 0021-9258. PMID 10409677.
Literatura[uredi | uredi kod]
- Petrova TV, Makinen T, Alitalo K (1999). „Signaling via vascular endothelial growth factor receptors.”. Exp. Cell Res. 253 (1): 117–30. DOI:10.1006/excr.1999.4707. PMID 10579917.
- Sato Y, Kanno S, Oda N i dr.. (2000). „Properties of two VEGF receptors, Flt-1 and KDR, in signal transduction”. Ann. N. Y. Acad. Sci. 902 (1): 201–5; discussion 205–7. DOI:10.1111/j.1749-6632.2000.tb06314.x. PMID 10865839.
- Boyd AW, Lackmann M (2002). „Signals from Eph and ephrin proteins: a developmental tool kit”. Sci. STKE 2001 (112): RE20. DOI:10.1126/stke.2001.112.re20. PMID 11741094.
- Luttun A, Tjwa M, Carmeliet P (2002). „Placental growth factor (PlGF) and its receptor Flt-1 (VEGFR-1): novel therapeutic targets for angiogenic disorders”. Ann. N. Y. Acad. Sci. 979: 80–93. DOI:10.1111/j.1749-6632.2002.tb04870.x. PMID 12543719.
- Maynard SE, Venkatesha S, Thadhani R, Karumanchi SA (2005). „Soluble Fms-like tyrosine kinase 1 and endothelial dysfunction in the pathogenesis of preeclampsia”. Pediatr. Res. 57 (5 Pt 2): 1R–7R. DOI:10.1203/01.PDR.0000159567.85157.B7. PMID 15817508.
- Shibuya M (2007). „Vascular endothelial growth factor receptor-1 (VEGFR-1/Flt-1): a dual regulator for angiogenesis”. Angiogenesis 9 (4): 225–30; discussion 231. DOI:10.1007/s10456-006-9055-8. PMID 17109193.
- Widmer M, Villar J, Benigni A i dr.. (2007). „Mapping the theories of preeclampsia and the role of angiogenic factors: a systematic review”. Obstetrics and gynecology 109 (1): 168–80. DOI:10.1097/01.AOG.0000249609.04831.7c. PMID 17197602.
- López-Novoa JM (2007). „Soluble endoglin is an accurate predictor and a pathogenic molecule in pre-eclampsia”. Nephrol. Dial. Transplant. 22 (3): 712–4. DOI:10.1093/ndt/gfl768. PMID 17210583.
- Poesen K, Lambrechts D i dr.. (2008). „Novel Role for Vascular Endothelial Growth Factor (VEGF)Receptor-1 and Its Ligand VEGF-B in Motor Neuron Degeneration”. J. Neurosci. 28 (42): 10451–9. DOI:10.1523/JNEUROSCI.1092-08.2008. PMID 18923022.
- Joukov V, Kaipainen A, Jeltsch M i dr.. (1997). „Vascular endothelial growth factors VEGF-B and VEGF-C”. J. Cell. Physiol. 173 (2): 211–5. DOI:10.1002/(SICI)1097-4652(199711)173:2<211::AID-JCP23>3.0.CO;2-H. PMID 9365524.
- Rosandra N. Kaplan, Rebecca D. Riba i dr.. (2005). „VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche”. Nature 438 (7069): 820–7. DOI:10.1038/nature04186. PMC 2945882. PMID 16341007.
PDB Galerija | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ||||||||||||
